Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

787 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study.
Lombardi F, Bruzzesi E, Bouba YR, Di Carlo D, Costabile V, Ranzenigo M, Maggiolo F, Castagna A, Callegaro AP, Zoncada A, Paolucci S, Micheli V, Renica S, Bezencheck A, Rossetti B, Santoro MM. Lombardi F, et al. AIDS Res Hum Retroviruses. 2024 Feb;40(2):80-89. doi: 10.1089/AID.2023.0015. Epub 2023 Jul 14. AIDS Res Hum Retroviruses. 2024. PMID: 37345697
Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.
Lombardi F, Belmonti S, Fabbiani M, Morandi M, Rossetti B, Tordini G, Cauda R, De Luca A, Di Giambenedetto S, Montagnani F. Lombardi F, et al. PLoS One. 2016 Jun 3;11(6):e0156523. doi: 10.1371/journal.pone.0156523. eCollection 2016. PLoS One. 2016. PMID: 27258647 Free PMC article.
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
Lombardi F, Belmonti S, Quiros-Roldan E, Latini A, Castagna A, D'Ettorre G, Gagliardini R, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S; AtLaS-M Study Group. Lombardi F, et al. J Antimicrob Chemother. 2017 Jul 1;72(7):2055-2059. doi: 10.1093/jac/dkx068. J Antimicrob Chemother. 2017. PMID: 28333353 Clinical Trial.
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
Belmonti S, Lombardi F, Quiros-Roldan E, Latini A, Castagna A, Borghetti A, Baldin G, Ciccullo A, Cauda R, De Luca A, Di Giambenedetto S; ATLAS-M Study Group. Belmonti S, et al. Among authors: lombardi f. J Antimicrob Chemother. 2018 Jul 1;73(7):1949-1954. doi: 10.1093/jac/dky125. J Antimicrob Chemother. 2018. PMID: 29788156 Clinical Trial.
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016.
Rossetti B, Di Giambenedetto S, Torti C, Postorino MC, Punzi G, Saladini F, Gennari W, Borghi V, Monno L, Pignataro AR, Polilli E, Colafigli M, Poggi A, Tini S, Zazzi M, De Luca A; Antiviral Response Cohort Analysis (ARCA) Collaborative Group. Rossetti B, et al. HIV Med. 2018 Oct;19(9):619-628. doi: 10.1111/hiv.12640. Epub 2018 Jun 22. HIV Med. 2018. PMID: 29932313 Free article.
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.
Quiros-Roldan E, Magro P, Raffetti E, Izzo I, Borghetti A, Lombardi F, Saracino A, Maggiolo F, Castelli F; MASTER Cohort. Quiros-Roldan E, et al. Among authors: lombardi f. BMC Infect Dis. 2018 Jun 25;18(1):285. doi: 10.1186/s12879-018-3198-2. BMC Infect Dis. 2018. PMID: 29940869 Free PMC article.
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study.
Gagliardini R, Ciccullo A, Borghetti A, Maggiolo F, Bartolozzi D, Borghi V, Pecorari M, Di Biagio A, Callegaro AP, Bruzzone B, Saladini F, Paolucci S, Maserati R, Zazzi M, Di Giambenedetto S, De Luca A; ARCA Study Group. Gagliardini R, et al. Open Forum Infect Dis. 2018 May 15;5(6):ofy113. doi: 10.1093/ofid/ofy113. eCollection 2018 Jun. Open Forum Infect Dis. 2018. PMID: 29977967 Free PMC article.
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'Autilia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A. Modica S, et al. Among authors: lombardi f. HIV Med. 2019 Feb;20(2):137-146. doi: 10.1111/hiv.12692. Epub 2018 Nov 21. HIV Med. 2019. PMID: 30461149 Free article.
787 results